Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: Preliminary results of a randomized phase III study (GC0301/TOP-002)

被引：0

作者：

Chin, K.

Iishi, H.

Imamura, H.

Kobayashi, O.

Imamoto, H.

Esaki, T.

Kato, M.

Tanaka, Y.

Furukawa, H.

机构：

[1] Canc Inst Hosp, Tokyo, Japan

[2] Osaka Med Ctr Canc & Cardiovasc, Osaka, Japan

[3] Sakai Municipal Hosp, Osaka, Japan

[4] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan

[5] Kinki Univ, Sch Med, Osaka, Japan

[6] Natl Kyushu Canc Ctr, Fukuoka, Fukuoka, Japan

[7] Hamanomachi Hosp, Fukuoka, Fukuoka, Japan

[8] Osaka Gen Med Ctr, Osaka, Japan

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4525

引用

页数：1